Clinical trial
International Single-Arm Protocol to Provide Expanded Access to Bortezomib for Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
NCT00440635 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- International Single-Arm Protocol to Provide Expanded Access to Bortezomib for Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
- Lead sponsor
- Janssen-Cilag International NV
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- October 31, 2006
- Enrollment
- 641 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.